Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 213 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Graft Rejection Clear all
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

NCT00099749
View directory record Official record
Conditions
Kidney Transplantation
Interventions
FTY 720
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
255 participants
Timeline
Started 2003
U.S. locations
5
States / cities
Maywood, Illinois • Springfield, Illinois • Livingston, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 5, 2026, 7:14 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

NCT03326076
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
Diagnostic Test · Other
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
72
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 5, 2026, 7:14 PM EDT
Completed No phase listed Observational

Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients

NCT04130685
View directory record Official record
Conditions
Pancreas Transplant Rejection, Kidney Transplant Rejection
Interventions
Allosure Test
Diagnostic Test
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 5, 2026, 7:14 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 5, 2026, 7:14 PM EDT
Recruiting No phase listed Observational

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

NCT06532890
View directory record Official record
Conditions
Cardiac Failure, Graft Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
Up to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 7:14 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 5, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

NCT02866682
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 5, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

The Effect of Rituximab on the Development of Anti-Donor Antibodies

NCT00695097
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Rituximab, No Rituximab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 5, 2026, 7:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 5, 2026, 7:14 PM EDT
Terminated Phase 3 Interventional

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187
View directory record Official record
Conditions
Corneal Diseases, Cornea Transplant
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 5, 2026, 7:14 PM EDT
Completed No phase listed Observational

Longitudinal Study of Cell Free DNA in Lung Transplant

NCT04234919
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 5, 2026, 7:14 PM EDT
Terminated Phase 4 Interventional Results available

A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity

NCT00983645
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Neoral
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 5, 2026, 7:14 PM EDT
Completed No phase listed Observational

The TOGETHER Project - Heart

NCT03833050
View directory record Official record
Conditions
Heart Transplant Rejection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 5, 2026, 7:14 PM EDT
Completed No phase listed Observational

Study of Heart Transplant Rejection

NCT00042614
View directory record Official record
Conditions
Heart Transplantation
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 5, 2026, 7:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

NCT03781414
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
CFZ533, Tacrolimus - MMF - corticosteroids
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 5, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

NCT00089947
View directory record Official record
Conditions
Renal Transplantation, Graft Rejection
Interventions
Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 5, 2026, 7:14 PM EDT
Recruiting No phase listed Observational

Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring

NCT07060716
View directory record Official record
Conditions
Kidney Transplant Rejection, Cell-free DNA
Interventions
donor-derived cell-free DNA test
Diagnostic Test
Lead sponsor
Insight Molecular Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 5, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

NCT00251004
View directory record Official record
Conditions
Kidney Transplantation, Graft Rejection
Interventions
Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 5, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Budesonide for Liver Transplant Immune Suppression

NCT03304626
View directory record Official record
Conditions
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Interventions
Budesonide 3Mg Capsule, Standard of Care Prednisone
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 5, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00096161
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions
Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 5, 2026, 7:14 PM EDT
Completed No phase listed Observational

Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung

NCT01793246
View directory record Official record
Conditions
Lung Neoplasms, Disorder Related to Lung Transplantation
Interventions
probe based laser endomicroscopy (pCLE)
Device
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 5, 2026, 7:14 PM EDT
Completed No phase listed Observational

T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays

NCT02382211
View directory record Official record
Conditions
Infection in Solid Organ Transplant Recipients
Interventions
Not listed
Lead sponsor
Oxford Immunotec
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Irvine, California • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 5, 2026, 7:14 PM EDT
Enrolling by invitation No phase listed Observational

Global Utilization And Registry Database for Improved preservAtion of doNor Livers

NCT05082077
View directory record Official record
Conditions
Liver Diseases, Liver Dysfunction, Liver Transplant Disorder, Liver Transplant Rejection
Interventions
LIVERguard
Device
Lead sponsor
Paragonix Technologies
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Stanford, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 5, 2026, 7:14 PM EDT
Terminated No phase listed Observational

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

NCT02300870
View directory record Official record
Conditions
Heart Transplantation
Interventions
Optison
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 5, 2026, 7:14 PM EDT